Literature DB >> 15790347

Interferons as pathogenic effectors in autoimmunity.

Roberto Baccala1, Dwight H Kono, Argyrios N Theofilopoulos.   

Abstract

Interferons (IFNs) type-1 (IFN alpha/beta) and type-II (IFN-gamma) are the most pleiotropic molecules in the intricate cytokine network. This dominance arises from three crucial factors: (i) initiation of IFN-alpha/beta and IFN-gamma production at the inception of most innate immune responses, which primes for the ensuing adaptive immune responses, primarily through the sine qua non upregulation of major histocompatibility complex and costimulatory molecules; (ii) magnification of their production and signaling by cross-talk between themselves, and synergistic or antagonistic effects on other cytokines; and (iii) direct or indirect initiation of transcription of hundreds of immunologically relevant genes. Considering that aberrant immune responses against self-molecules seem to depend on the same constituents and pathways as those against exogenous antigens, it follows that IFNs are also major effectors in the pathogenesis of autoimmunity. Here, we review the diverse biological effects of IFNs on the immune system, discuss findings pertaining to the nature of exogenous and endogenous stimuli that might induce IFN production through the engagement of Toll-like receptors, and summarize the detrimental and, in some instances, beneficial effects of IFNs in systemic and organ-specific autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790347     DOI: 10.1111/j.0105-2896.2005.00252.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  74 in total

1.  Altered Toll-like receptor signaling pathways in human type 1 diabetes.

Authors:  Adam J Meyers; Roopali R Shah; Peter A Gottlieb; Danny Zipris
Journal:  J Mol Med (Berl)       Date:  2010-08-20       Impact factor: 4.599

Review 2.  Interferon-γ and systemic autoimmunity.

Authors:  Kenneth M Pollard; David M Cauvi; Christopher B Toomey; Kevin V Morris; Dwight H Kono
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

3.  Treatment of neuromyelitis optica: current debate.

Authors:  Tomoko Okamoto; Masafumi Ogawa; Youwei Lin; Miho Murata; Sachiko Miyake; Takashi Yamamura
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

4.  Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons.

Authors:  Jieliang Li; Shuxian Hu; Lin Zhou; Li Ye; Xu Wang; Jie Ho; Wenzhe Ho
Journal:  Glia       Date:  2010-09-27       Impact factor: 7.452

5.  Association of interferon-gamma gene polymorphism (+874A) with arthritis manifestation in SLE.

Authors:  Marut Tangwattanachuleeporn; Pimpayao Sodsai; Yingyos Avihingsanon; Jongkonnee Wongpiyabovorn; Jeerapat Wongchinsri; Nattiya Hirankarn
Journal:  Clin Rheumatol       Date:  2007-08-23       Impact factor: 2.980

6.  An immune competent mouse model for the characterization of recombinant measles vaccines.

Authors:  René R Marty; Marlyse C Knuchel; Teldja Neige Azzouz Morin; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 7.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

8.  Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.

Authors:  Kazuyoshi Takeda; Yuko Kojima; Kenichi Ikejima; Kenichi Harada; Shunhei Yamashina; Kyoko Okumura; Tomonori Aoyama; Steffen Frese; Hiroko Ikeda; Nicole M Haynes; Erika Cretney; Hideo Yagita; Noriyoshi Sueyoshi; Nobuhiro Sato; Yasuni Nakanuma; Mark J Smyth; Ko Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-30       Impact factor: 11.205

9.  Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.

Authors:  Robert B Couch; Robert L Atmar; Thomas R Cate; John M Quarles; Wendy A Keitel; Nancy H Arden; Janet Wells; Diane Niño; Philip R Wyde
Journal:  Vaccine       Date:  2009-07-14       Impact factor: 3.641

Review 10.  Cytokines in Sjögren's syndrome.

Authors:  N Roescher; P P Tak; G G Illei
Journal:  Oral Dis       Date:  2009-06-10       Impact factor: 3.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.